Natural Capsules Limited (NSE:NATCAPSUQ) filed an exchange notice on 18 August 2026 convening an Extraordinary General Meeting on 9 September 2026 at 12:00 PM IST via video conferencing, to seek shareholder approval for two preferential allotment resolutions involving equity shares and convertible warrants.
Key Highlights
- The EGM is scheduled for Wednesday, 9 September 2026 at 12:00 PM IST, to be held through video conferencing or other audio-visual means.
- Resolution 1 proposes issuing 1,25,000 equity shares at Rs 160 per share to promoter Mr. Sunil Laxminarayan Mundra, aggregating Rs 2,00,00,000 in total issue size.
- Resolution 2 seeks approval for issuance of warrants convertible into equity shares on a preferential basis, also subject to shareholder approval as a special resolution.
- The relevant date for determining the minimum issue price under SEBI ICDR Regulations is 10 August 2026, being 30 days prior to the EGM date.
About the Company
Natural Capsules Limited (NSE:NATCAPSUQ) is a Bengaluru-headquartered manufacturer of hard gelatin and two-piece capsule shells, primarily used by pharmaceutical and nutraceutical companies. The company operates in the pharma packaging and capsule manufacturing segment and is listed on both BSE (scrip code 524654) and NSE. Its registered office is located in Jayanagar, Bangalore.
Announcement in Detail
The EGM notice, filed under Regulation 30 of the SEBI Listing Regulations, places two special resolutions before shareholders. The first resolution proposes allotting 1,25,000 fully paid-up equity shares at Rs 160 per share to Mr. Sunil Laxminarayan Mundra, classified as an individual promoter, on a private placement basis. The total consideration amounts to Rs 2,00,00,000. Shares are to be allotted in dematerialised form within 15 days of the special resolution being passed, or within 15 days of the last regulatory approval if such approvals are required.
The second resolution covers the issuance of warrants convertible into equity shares on a preferential basis, also to be approved as a special resolution. Both resolutions are framed under Sections 23(1)(b), 42, and 62(1)(c) of the Companies Act, 2013, read with SEBI ICDR Regulations, 2018. The pre-preferential and post-allotment shareholding of the proposed allottee will be subject to lock-in as prescribed under Chapter V of the SEBI ICDR Regulations.
Impact on Investors
Investors will note that both resolutions, if passed, will increase the total equity share capital of Natural Capsules Limited (NSE:NATCAPSUQ), resulting in dilution for existing shareholders. The filing shows that the allottee is a promoter, meaning the preferential allotment, if approved, will likely increase promoter shareholding relative to the current public float. Shareholders will observe that the issue price of Rs 160 per share is determined by the SEBI ICDR floor price methodology, with the relevant date fixed at 10 August 2026.
The disclosed terms indicate that the new shares will rank pari passu with existing equity shares in all respects, including dividend entitlement and voting rights, from the date of allotment. The warrant resolution remains partially disclosed in the available filing extract, so shareholders are advised to review the complete EGM notice before the meeting date.
Sector / Market Context
India's pharmaceutical capsule and drug delivery components sector has seen consistent demand, supported by the country's position as one of the world's largest generic drug exporters. According to Pharmaceuticals Export Promotion Council of India data, Indian pharma exports have grown steadily, sustaining upstream demand for capsule shell manufacturers. Preferential allotments to promoters in small and mid-cap pharma companies have been a recurring fund-raising route under the SEBI ICDR framework, particularly where the amounts involved are below Rs 5 crore and require only shareholder approval rather than institutional participation.